Skip to content

RANDOMIZED MULTICENTRIC, DOUBLE-BLIND STUDY OF THE EFFECTIVENESS AND TOLERANCE OF DEXECADOTRIL VS. RACECADOTRIL, IN THE TREATMENT OF AQUEOUS WATER DIARRHEA IN CHILDREN.

RANDOMIZED MULTICENTRIC, DOUBLE-BLIND STUDY OF THE EFFECTIVENESS AND TOLERANCE OF DEXECADOTRIL VS. RACECADOTRIL, IN THE TREATMENT OF AQUEOUS WATER DIARRHEA IN CHILDREN.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-035-03
Enrollment
26
Registered
2003-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dexecadotril Type of group
One takes immediately to the inclusion, followed by 3 daily doses, without exceeding 7 days. Group name:Racecadotril Type of group
One takes immediately to the inclusion, followed by 3 daily doses, without exceeding 7 days.

Sponsors

BIOPROJET,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - male patient older than 1 month and younger than 3 years, - suffering from acute diarrhea, of presumed infectious origin, defined as a sudden increase in the number of stools characterized by the following 3 mandatory criteria: * at least 3 or more watery or loose stools within the last 24 hours, * Duration of diarrhea (from first diarrheal stool): at least 24 hours and not more than 72 hours until the moment of inclusion * the child requires hospitalization - written informed consent of the parents.

Exclusion criteria

Exclusion criteria: - previous episode of diarrhea within the last 2 weeks. - presence of blood in the stools. - the patient has received treatment with an antibiotic at therapeutic or acid doses acetylsalicylic, or some anti-diarrheic, within 72 hours before its inclusion. - Severe malnutrition defined as a weight index for height less than 70% of the average NCSH, - presence of any other disease or condition that requires antibiotic therapy at the time of its inclusion. - Severe dehydration requiring intravenous rehydration. - Known hypersensitivity to racecadotril. - concomitant disease that may interfere with the study. - patients participating in another study, or who have participated in another study the previous month, or have already participated in this study.

Design outcomes

Primary

MeasureTime frame
Outcome name:The weight of stools in the first 48 hours. Measure:VALUATION OF THE SEVERITY OF THE DIARRHEA Timepoints:48 hours

Secondary

MeasureTime frame
Outcome name:• the discharge of stool from the first 24 hours. • the total discharge of stool until recovery. • the recovery percentage at the last visit. • the duration of diarrhea (period between the first intake of treatment [HO] and the last deposition not formed before recovery). • the total intake of the oral rehydration solution. • total volume of vomiting. • Subgroup analysis according to rotavirus status (positive or negative). Measure:VALUATION OF THE SEVERITY OF THE DIARRHEA Timepoints:24 hours

Countries

Peru, United States

Outcome results

None listed

Source: REPEC (via WHO ICTRP)